Neuropace (NPCE) Earnings Date & Reports

Key Takeaways

• NeuroPace, Inc. (NPCE) is scheduled to report third-quarter 2026 results after the market close on Thursday, November 12, 2026.
• Analysts expect a narrower loss of roughly $0.09 per share on revenue near $27.1 million, according to available consensus data.
• The RNS (responsive neurostimulation) System remains the core growth driver, with management guiding to 21%–23% full-year RNS revenue growth.
• Investors will closely watch updates on the idiopathic generalized epilepsy (IGE) regulatory pathway and full-year 2026 guidance.
• The company has beaten consensus EPS estimates in seven of its last eight quarters, raising the bar for continued execution.
• For more context, explore NeuroPace's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Explore Trending AI Robots for additional automated trading and market insights.

Earnings Context and Why It Matters

NeuroPace's third-quarter 2026 report carries outsized weight for investors because the company is at a pivotal point in its commercial trajectory. Over the past several quarters, the medical device maker has delivered accelerating RNS System sales, record levels of active prescribers and patient pipeline, and steady improvements toward profitability. The company has raised its full-year revenue outlook twice in 2026, reflecting stronger visibility into core demand. At the same time, NeuroPace is pursuing a potential FDA (U.S. Food and Drug Administration) expansion into IGE, a substantially larger patient population. This print will help investors gauge whether the growth narrative remains intact heading into 2027.

Earnings Expectations

For the third quarter of 2026, consensus estimates point to a loss of approximately $0.09 per share on revenue of about $27.1 million. In the same period a year earlier, NeuroPace reported a loss of $0.11 per share on revenue of $27.35 million, suggesting analysts expect modest margin improvement despite a slightly softer top-line comparison. Revenue comparisons are influenced by the wind-down of the DIXI Medical business, which is now presented as discontinued operations.

RNS System revenue is the metric to watch most closely. Management has guided to full-year RNS growth of 21%–23% and recently narrowed the total revenue outlook to $99.5–$101.5 million. Investors will also focus on adjusted gross margin (guided to 82%–83%), adjusted operating expenses, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), where the company expects a full-year loss of $7.5–$8.5 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to refine your own watchlist and uncover opportunities aligned with your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter print is broadly constructive but measured. NeuroPace shares have been volatile in 2026, and the stock has historically reacted to how results compare with consensus and to any changes in full-year guidance. The company has beaten EPS estimates in seven of the last eight quarters, which has conditioned investors to expect disciplined execution. Key risk factors include the timing of the FDA decision on the IGE indication expansion, potential margin pressure from material costs, and any softness in procedural volumes. A guidance update—particularly around RNS growth or the IGE timeline—could prove more consequential for the stock than the headline earnings figures themselves.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter report, the single most important catalyst remains NeuroPace's effort to expand the RNS System's indication into IGE. Management has reiterated expectations for a midyear FDA determination tied to the NAUTILUS PMA (premarket approval) supplement, supported by the device's breakthrough designation. An approval would meaningfully expand the company's addressable market.

Investors should also track commercial execution metrics, including active prescribers, accounts, and patient pipeline, which management has cited as leading indicators of future demand. The company's AI initiatives, such as the ECoG Assistant platform and a multimodal foundational AI model built on more than 27 million intracranial EEG (electroencephalogram) recordings, represent a longer-term growth lever worth monitoring.

Finally, keep an eye on the balance sheet and cash burn. NeuroPace ended the second quarter with about $51.7 million in cash, equivalents, and short-term investments, along with long-term borrowings near $59 million. As the company invests in commercial infrastructure and product development, its path toward sustained profitability and cash-flow breakeven will remain a central theme for investors evaluating the stock's risk profile.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations